ArticlePloS one2011
A novel peptide derived from human apolipoprotein E is an inhibitor of tumor growth and ocular angiogenesis.
Article in PloS one, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 1 synthesis or guideline pooled it, 32 citations in OpenAlex.
- Association between apolipoprotein E genotype and cancer susceptibility: a meta-analysis.Journal of cancer research and clinical oncology · 2014Pooled it
- Review
- Jun-APOE-LRP1 axis promotes tumor metastasis in colorectal cancer.Biomolecules & biomedicine · 2023Article
- Deliver protein across bio-barriers via hexa-histidine metal assemblies for therapy: a case in corneal neovascularization model.Materials today. Bio · 2021Article
- Apolipoprotein mimetics in cancer.Seminars in cancer biology · 2021Review
- Apolipoproteins, as the carrier proteins for lipids, are involved in the development of breast cancer.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2020Review
- Atherosclerotic Pre-Conditioning Affects the Paracrine Role of Circulating Angiogenic Cells Ex-Vivo.International journal of molecular sciences · 2020Article
- The inhibitory effect of different concentrations of KH902 eye drops on corneal neovascularization induced by alkali burn.Indian journal of ophthalmology · 2017Article
- LRP-1 Pathway Targeted Inhibition of Vascular Abnormalities in the Retina of Diabetic Mice.Current eye research · 2017Article
- Design of growth factor sequestering biomaterials.Chemical communications (Cambridge, England) · 2014Review
- Predicting response to vascular endothelial growth factor inhibitor and chemotherapy in metastatic colorectal cancer.BMC cancer · 2014Article
- Specific VEGF sequestering to biomaterials: influence of serum stability.Acta biomaterialia · 2013Article
- Expression and clinical significance of apolipoprotein E in pancreatic ductal adenocarcinoma.Medical oncology (Northwood, London, England) · 2013Article
- High-glucose-induced endothelial cell injury is inhibited by a Peptide derived from human apolipoprotein E.PloS one · 2012Article
- Ocular herpes simplex virus: how are latency, reactivation, recurrent disease and therapy interrelated?Future microbiology · 2011Review
- KH906, a recombinant human VEGF receptor fusion protein, is a new effective topical treatment for corneal neovascularization.Molecular vision · 2011Article
- Design of Anti-Angiogenic Peptidomimetics and Evaluation their Biological Activity byAvicenna journal of medical biotechnologyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 2 institutions in 1 country.
Funding
Abstract
Angiogenesis is a hallmark of tumor development and metastasis and now a validated target for cancer treatment. We previously reported that a novel dimer peptide (apoEdp) derived from the receptor binding region of human apolipoprotein E (apoE) inhibits virus-induced angiogenesis. However, its role in tumor anti-angiogenesis is unknown. This study demonstrates that apoEdp has anti-angiogenic property in vivo through reduction of tumor growth in a mouse model and ocular angiogenesis in a rabbit eye model. Our in vitro studies show that apoEdp inhibits human umbilical vein endothelial cell proliferation, migration, invasion and capillary tube formation. We document that apoEdp inhibits vascular endothelial growth factor-induced Flk-1 activation as well as downstream signaling pathways that involve c-Src, Akt, eNOS, FAK, and ERK1/2. These in vitro data suggest potential sites of the apoE dipeptide inhibition that could occur in vivo.This is the first evidence that a synthetic dimer peptide mimicking human apoE has anti-angiogenesis functions and could be an anti-tumor drug candidate.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.